CL2018000668A1 - Plataforma de andamio con nudo de tierra. - Google Patents

Plataforma de andamio con nudo de tierra.

Info

Publication number
CL2018000668A1
CL2018000668A1 CL2018000668A CL2018000668A CL2018000668A1 CL 2018000668 A1 CL2018000668 A1 CL 2018000668A1 CL 2018000668 A CL2018000668 A CL 2018000668A CL 2018000668 A CL2018000668 A CL 2018000668A CL 2018000668 A1 CL2018000668 A1 CL 2018000668A1
Authority
CL
Chile
Prior art keywords
scaffold platform
unnatural origin
knot
bind
ckp
Prior art date
Application number
CL2018000668A
Other languages
English (en)
Spanish (es)
Inventor
Rami Hannoush
Harini Kaluarachchi
Aaron NILE
Cameron Noland
Yingnan Zhang
Lijuan Zhou
Xinxin Gao
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2018000668A1 publication Critical patent/CL2018000668A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
CL2018000668A 2015-09-15 2018-03-13 Plataforma de andamio con nudo de tierra. CL2018000668A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562219063P 2015-09-15 2015-09-15

Publications (1)

Publication Number Publication Date
CL2018000668A1 true CL2018000668A1 (es) 2018-07-20

Family

ID=57068206

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2018000668A CL2018000668A1 (es) 2015-09-15 2018-03-13 Plataforma de andamio con nudo de tierra.
CL2020001781A CL2020001781A1 (es) 2015-09-15 2020-07-02 Un péptido de nudo de cistina (ckp) de origen no natural que se une a la proteína relacionada con el receptor de lipoproteína de baja densidad 6 (lrp6) humana. (divisional solicitud 201800668)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2020001781A CL2020001781A1 (es) 2015-09-15 2020-07-02 Un péptido de nudo de cistina (ckp) de origen no natural que se une a la proteína relacionada con el receptor de lipoproteína de baja densidad 6 (lrp6) humana. (divisional solicitud 201800668)

Country Status (22)

Country Link
US (8) US10428125B2 (OSRAM)
EP (1) EP3350215B1 (OSRAM)
JP (2) JP7166916B2 (OSRAM)
KR (1) KR102846388B1 (OSRAM)
CN (4) CN114805528A (OSRAM)
AR (1) AR106032A1 (OSRAM)
AU (2) AU2016323445B2 (OSRAM)
BR (1) BR112018002263A2 (OSRAM)
CA (1) CA2996006A1 (OSRAM)
CL (2) CL2018000668A1 (OSRAM)
CO (1) CO2018002510A2 (OSRAM)
CR (1) CR20180169A (OSRAM)
IL (2) IL257399B (OSRAM)
MA (1) MA42828A (OSRAM)
MX (1) MX2018002922A (OSRAM)
MY (1) MY190552A (OSRAM)
PE (1) PE20181293A1 (OSRAM)
PH (1) PH12018500577A1 (OSRAM)
RU (1) RU2770384C2 (OSRAM)
TW (1) TWI799366B (OSRAM)
UA (1) UA125505C2 (OSRAM)
WO (1) WO2017049009A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2019233605A1 (en) * 2018-06-08 2019-12-12 BioNTech SE Compositions and methods for diagnosis and treatment of cancer
JP2023529203A (ja) 2020-06-11 2023-07-07 ジェネンテック， インコーポレイテッド ナノリポタンパク質－ポリペプチドコンジュゲート並びにそれを使用する組成物、システム、及び方法
WO2025193946A2 (en) * 2024-03-14 2025-09-18 Genentech, Inc. Peptides binding lrrc15 and uses thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US918814A (en) 1907-10-30 1909-04-20 Handy Mfg Company Funnel.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3319594B2 (ja) 1990-03-20 2002-09-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 定常領域の代わりに受容体結合性リガンドを有するキメラ抗体
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
PL199659B1 (pl) 1998-02-25 2008-10-31 Merck Patent Gmbh Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1268544A2 (en) 2000-03-31 2003-01-02 Institut Pasteur Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
EP1290169A2 (en) 2000-06-01 2003-03-12 Amgen, Inc. Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
EP2316394B1 (en) 2001-06-12 2016-11-23 The Johns Hopkins University Reservoir device for intraocular drug delivery
AU2002340080A1 (en) 2001-10-03 2003-04-14 Regeneron Pharmaceuticals, Inc. Anti-angiogenic peptides
GB0130738D0 (en) * 2001-12-21 2002-02-06 Serono Internat S A Protein
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
DE102005002978B4 (de) 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
PL1844337T3 (pl) 2005-01-24 2013-12-31 Pepscan Systems Bv Związki wiążące, związki immunogenne i peptydomimetyki
US20060204548A1 (en) 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
CA2614358A1 (en) 2005-06-29 2007-01-04 Roselli, Patrizia Agonistic and antagonistic peptide mimetics of the vegf alpha-helix binding region for use in therapy
US20070191272A1 (en) * 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
CN101583370A (zh) * 2005-09-27 2009-11-18 阿穆尼克斯公司 蛋白质药物及其用途
TW200732347A (en) * 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use
WO2007131050A2 (en) 2006-05-02 2007-11-15 Georgia Tech Research Corporation Method for drug delivery to ocular tissue using microneedle
WO2008045252A2 (en) * 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
CA2670990A1 (en) 2006-12-01 2008-06-12 Allergan, Inc. Method for determining optimum intraocular locations for drug delivery systems
CA3076115C (en) 2007-08-21 2022-06-28 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
PL2274008T3 (pl) * 2008-03-27 2014-07-31 Zymogenetics Inc Kompozycje i sposoby hamowania PDGFRbeta i VEGF-A
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
EP2349327A4 (en) * 2008-10-23 2012-11-28 Massachusetts Inst Technology COMMITMENT DIRECTED FC RECEIVERS ACTIVATORS
CN102272148A (zh) * 2008-11-03 2011-12-07 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
PL2391419T3 (pl) 2009-01-29 2019-12-31 Forsight Vision4, Inc. Dostarczanie leku do tylnego odcinka
US8778888B2 (en) * 2009-11-06 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
US20110207653A1 (en) 2009-12-21 2011-08-25 Adrian Raiche Microparticle Encapsulated Thiol-Containing Polypeptides Together with a Redox Reagent
CA2785468A1 (en) 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
US8339139B2 (en) * 2010-01-29 2012-12-25 Infineon Technologies Ag System and method for testing a circuit
US10844106B2 (en) * 2010-11-08 2020-11-24 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
BR112013020874A2 (pt) * 2011-02-18 2019-05-21 Endo Pharmaceuticals Inc. composto, regime, método para a preparação do referido composto, e, uso de um composto
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
EP2890389A1 (en) * 2012-08-28 2015-07-08 Novartis AG Use of a vegf antagonist in treating ocular vascular proliferative diseases
GB201218278D0 (en) * 2012-10-11 2012-11-28 Cyclogenix Ltd Translocating peptide
WO2014063012A1 (en) * 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺

Also Published As

Publication number Publication date
MY190552A (en) 2022-04-27
CN114591422A (zh) 2022-06-07
CN114591422B (zh) 2025-04-04
US20170129927A1 (en) 2017-05-11
US11155586B2 (en) 2021-10-26
US20200115424A1 (en) 2020-04-16
WO2017049009A8 (en) 2018-02-22
BR112018002263A2 (en) 2018-09-18
JP2018533912A (ja) 2018-11-22
KR20180052718A (ko) 2018-05-18
JP7166916B2 (ja) 2022-11-08
US11078243B2 (en) 2021-08-03
RU2770384C2 (ru) 2022-04-15
NZ740218A (en) 2025-05-02
US20200140498A1 (en) 2020-05-07
TW201717993A (zh) 2017-06-01
US20200231636A1 (en) 2020-07-23
TWI799366B (zh) 2023-04-21
EP3350215B1 (en) 2025-12-03
AU2016323445A1 (en) 2018-03-01
US10696721B2 (en) 2020-06-30
PE20181293A1 (es) 2018-08-07
IL257399A (en) 2018-04-30
KR102846388B1 (ko) 2025-08-18
AU2021204400B2 (en) 2023-02-02
IL294568A (en) 2022-09-01
IL257399B (en) 2022-08-01
US20200325187A1 (en) 2020-10-15
CN108026162A (zh) 2018-05-11
CN114805528A (zh) 2022-07-29
PH12018500577A1 (en) 2018-10-15
US20230174596A1 (en) 2023-06-08
US10428125B2 (en) 2019-10-01
EP3350215A1 (en) 2018-07-25
CN108026162B (zh) 2022-04-05
MX2018002922A (es) 2018-06-07
US20240247034A1 (en) 2024-07-25
MA42828A (fr) 2018-07-25
CA2996006A1 (en) 2017-03-23
WO2017049009A1 (en) 2017-03-23
US11407794B2 (en) 2022-08-09
RU2018113442A3 (OSRAM) 2020-02-17
CL2020001781A1 (es) 2020-10-23
CN120248097A (zh) 2025-07-04
CR20180169A (es) 2018-04-24
JP7602514B2 (ja) 2024-12-18
HK1253318A1 (zh) 2019-06-14
UA125505C2 (uk) 2022-04-13
AU2016323445B2 (en) 2021-04-01
CO2018002510A2 (es) 2018-05-31
AR106032A1 (es) 2017-12-06
AU2021204400A1 (en) 2021-07-22
RU2018113442A (ru) 2019-10-16
US20180291069A1 (en) 2018-10-11
JP2022130481A (ja) 2022-09-06

Similar Documents

Publication Publication Date Title
MX2021009673A (es) Moduladores de ror-gamma.
MX2017003268A (es) Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
MX2017016838A (es) Construcciones dirigidas a complejos de peptido de ny-eso-1/complejo principal de histocompatibilidad (mhc) y usos de los mismos.
CO2019010503A2 (es) Plataforma de identificación de péptidos inmunogénicos personalizada
AR109625A1 (es) Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas
PE20200617A1 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
SV2017005486A (es) Anticuerpos a tau y usos de los mismos
MX2017014818A (es) Agonistas de triazol del receptor apj.
UY37456A (es) Inmunoglobulinas y sus usos
CL2018000668A1 (es) Plataforma de andamio con nudo de tierra.
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
AR095611A1 (es) Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1)
CO6630181A2 (es) Composiciones y métodos para uso de anticuerpos terapéuticos de lrp6( proteina relacionada con lipoproteínas de baja densidad 6)
MX2017004148A (es) Composiciones, kits y metodos para inducir citorresistencia adquirida usando inductores de proteinas de estres.
DOP2017000073A (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
UY36663A (es) Anticuerpos anti-ap2 y agentes de unión al antígeno para tratar trastornos metabólicos
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
EA201992883A1 (ru) АНТИТЕЛА К TrkB
BR112018003714A2 (pt) composições de ácido de peso aumentado que compreendem aminoácidos
MX2018003445A (es) Expresion de proteinas que contienen fc.
ECSP17015154A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo